Investment Analysts’ Weekly Ratings Changes for Reata Pharmaceuticals (RETA)

Several brokerages have updated their recommendations and price targets on shares of Reata Pharmaceuticals (NASDAQ: RETA) in the last few weeks:

  • 2/7/2018 – Reata Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “
  • 1/31/2018 – Reata Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/31/2018 – Reata Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “
  • 1/24/2018 – Reata Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. “
  • 1/20/2018 – Reata Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/14/2017 – Reata Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.

Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) opened at $26.22 on Monday. Reata Pharmaceuticals Inc has a fifty-two week low of $19.48 and a fifty-two week high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15. The company has a market cap of $684.68, a P/E ratio of -17.14 and a beta of -2.52.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.11). The firm had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $12.54 million. The business’s revenue was up .0% on a year-over-year basis. sell-side analysts forecast that Reata Pharmaceuticals Inc will post -1.91 EPS for the current year.

In other news, major shareholder James W. Traweek, Jr. purchased 17,000 shares of the business’s stock in a transaction dated Friday, December 29th. The shares were purchased at an average price of $28.47 per share, for a total transaction of $483,990.00. Following the completion of the acquisition, the insider now directly owns 35 shares in the company, valued at approximately $996.45. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director R Kent Mcgaughy, Jr. purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, December 27th. The shares were purchased at an average price of $25.83 per share, for a total transaction of $387,450.00. Following the acquisition, the director now owns 25,004 shares of the company’s stock, valued at $645,853.32. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 413,813 shares of company stock worth $10,453,354. Corporate insiders own 44.00% of the company’s stock.

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply